Skip to main content

Advertisement

Fig. 1 | BMC Medical Genetics

Fig. 1

From: Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms

Fig. 1

Study design. All recruited MPN patients were initially screened for BCR-ABL transcripts to differentiate BCR-ABL positive or negative MPN patients using real time PCR. All 105 MPN patients BCR-ABL transcripts negative were subjected to an ARMS-PCR method to screen for the presence or absence of the Jak2 V617F mutation. Irrespective of the presence or absence of wildtype or mutant, all 105 MPN patients were subjected to an in-house developed PCR based protocol (ALDA -amplicon length differentiation assay) for simultaneous detection of CALR type-1 and CALR type-2 mutations. Furthermore the ALDA assay was comparatively evaluated with Sanger sequencing and other available real-time PCR methodologies as described by Zinke et. al [13]

Back to article page